Cellect Biotechnology to Present at the 2020 Cell & Gene Meeting on the Mesa
September 21 2020 - 8:30AM
Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of
innovative technology which enables the functional selection of
cells facilitating safer and more efficacious cell and gene
therapies, today announced that the leadership will be presenting
at the Cell & Gene Meeting on the Mesa, which is being held
from October 12th – 16th. In addition to providing an overview of
the Company, the management team will provide a progress update on
the clinical and development programs and an overview of the
Company’s business strategy. Management will be virtually meeting
cell and gene therapy companies to support collaborations.
“This is one of the most prestigious meetings
for our industry, and despite it being virtual this year due to the
COVID-19 pandemic, it will not dampen our enthusiasm” commented Dr.
Yarkoni. We have successfully adjusted our operations, and we
continue to make significant progress with our Israel and
U.S.-based clinical trials. We are also taking meaningful steps to
accelerate nearer-term revenue opportunities as we are
collaborating with several partners that are looking to leverage
our technology platform to help improve their products, especially
in high-growth areas such as CAR T, NK (natural killers) and MSC’s.
We are looking forward to sharing the progress we have made and
also look forward to meeting with current and potential partners
developing cell and gene therapies.”
To schedule a meeting with the Company’s Chief
Executive Officer, Dr. Shai Yarkoni or Chief Operating Officer,
Amos Ofer, please request a meeting through the meeting portal
and/or contact the Company direct at shai@cellect.co or
amoso@cellect.co. The presentation will be available on the
Company’s website prior to the commencement of the meeting. The
Cell & Gene Meeting on the Mesa is the sector’s foremost annual
conference bringing together senior executives and top
decision-makers in the industry to advance cutting-edge research
into cures.
About Cellect Biotechnology
Ltd.
Cellect Biotechnology (APOP) has developed a
breakthrough technology, for the functional selection of cells that
aims to improve the robustness, safety and efficacy of a variety of
cell and gene therapies. The Company’s technology can be used by
researchers, clinical community and pharma companies in a wide
variety of applications including next generation Car T, NK, MSC
and gene therapies.
The Company is also developing its own product
that is an improved BMT which is in a current clinical trial for
cancer treatment.
Forward Looking Statements
This press release contains forward-looking
statements about the Company’s expectations, beliefs and
intentions. Forward-looking statements can be identified by the use
of forward-looking words such as “believe”, “expect”, “intend”,
“plan”, “may”, “should”, “could”, “might”, “seek”, “target”,
“will”, “project”, “forecast”, “continue” or “anticipate” or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. For example, forward-looking statements are
used in this press release when we discuss Cellect’s expectations
regarding timing of the commencement of its planned U.S. clinical
trial and its plan to reduce operating costs. These forward-looking
statements and their implications are based on the current
expectations of the management of the Company only and are subject
to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the
forward-looking statements. In addition, historical results or
conclusions from scientific research and clinical studies do not
guarantee that future results would suggest similar conclusions or
that historical results referred to herein would be interpreted
similarly in light of additional research or otherwise. The
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: the Company’s history of losses and needs for
additional capital to fund its operations and its inability to
obtain additional capital on acceptable terms, or at all; the
Company’s ability to continue as a going concern; uncertainties of
cash flows and inability to meet working capital needs; the
Company’s ability to obtain regulatory approvals; the Company’s
ability to obtain favorable pre-clinical and clinical trial
results; the Company’s technology may not be validated and its
methods may not be accepted by the scientific community;
difficulties enrolling patients in the Company’s clinical trials;
the ability to timely source adequate supply of FasL; risks
resulting from unforeseen side effects; the Company’s ability to
establish and maintain strategic partnerships and other corporate
collaborations; the scope of protection the Company is able to
establish and maintain for intellectual property rights and its
ability to operate its business without infringing the intellectual
property rights of others; competitive companies, technologies and
the Company’s industry; unforeseen scientific difficulties may
develop with the Company’s technology; the Company’s ability to
retain or attract key employees whose knowledge is essential to the
development of its products; and the Company’s ability to pursue
any strategic transaction or that any transaction, if pursued, will
be completed. Any forward-looking statement in this press release
speaks only as of the date of this press release. The Company
undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading “Risk Factors” in Cellect Biotechnology Ltd.’s Annual
Report on Form 20-F for the fiscal year ended December 31, 2019
filed with the U.S. Securities and Exchange Commission, or SEC,
which is available on the SEC’s website, www.sec.gov, and in the
Company’s periodic filings with the SEC.
ContactCellect Biotechnology
Ltd.Eyal Leibovitz, Chief Financial
Officerwww.cellect.co+972-9-974-1444
Or
EVC Group LLCMichael Polyviou(732)
933-2754mpolyviou@evcgroup.com
WWW.CELLECTBIO.COM |
E N A B L I N G S T E M C E L L S |
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Jul 2023 to Jul 2024